top of page
owenhaskins

GT Metabolic's MagDI System for side-to-side DI anastomosis to "revolutionise industry" after FDA approval

GT Metabolic Solutions has received FDA clearance of its MagDI System for side-to-side duodeno-ileal (DI) anastomosis. The MagDI System is the first-of-its-kind minimally invasive surgical technique to create anastomosis without foreign materials left behind.


Paul Enochs alongside GT Metabolic MagDI System inventor Michel Gagner, perform a side-to-side duodeno-ileal (DI) anastomosis

"It's a paradigm shift creating a new standard of care that democratizes anastomosis creation," said Dr Michel Gagner, inventor of the device, chief medical officer and co-founder of GT Metabolic. "We're providing the surgical community with a novel approach to minimally invasive surgery shown to have zero bleeds and zero leaks. Suturing and stapling bowel tissue for anastomosis creation will become outdated. Magnetic compression anastomosis technology will revolutionise the industry."



The MagDI System is composed of the GT Metabolic linear DI magnets, the GT Metabolic delivery system, and the GT Metabolic laparoscopic positioning device (LPD). During the MagDI procedure two linear magnets are delivered orogastrically to the patient. The magnets are positioned laparoscopically and self-align through the small bowel. After several weeks the magnets compress the tissue fusing together forming an anastomosis. The magnets detach and are expressed naturally.

Self-aligning GT Metabolic MagDI System magnets fused together

The anastomosis created with magnet compressions happens without the cutting or piercing of intestinal tissue that occurs with the current practice of stapling or suturing. The MagDI System is designed for more consistent tissue alignment, central necrosis, and circumferential healing while leaving no foreign materials behind to impede the natural tissue healing process.


The MagDI System was cleared after clinical data submitted to the FDA showed the system performed as intended. In all subjects, the MagDI System created patent side-to-side duodeno-ileal anastomosis. There were no reports of anastomotic bleeding, leakage or obstruction.


GT Metabolic is currently identifying key sites for additional clinical studies. Key opinion leaders in the bariatric surgery specialty interested in participating in the MagDI System launch can contact the company at GT Metabolic.


"With this FDA clearance, the MagDI System is poised to launch a new frontier in healthcare as we continue to deliver on our visionary milestones for efficacy in magnetic surgery," said MedTech entrepreneur Thierry Thaure, CEO and co-founder of GT Metabolic. "After completing over 100 cases in seven clinical trials across eight countries, launching in the US market with this groundbreaking technology is a major progression in our journey to advance minimally invasive surgery in the bariatric space as well as in future areas."

Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Thanks for submitting!

Get in touch!
Email: info@bariatricnews.net

©2023 Dendrite Clinical Systems Ltd. All rights reserved.
No part of this website may be reproduced, stored in a retrieval system, transmitted in any form or by any other means without prior written permission from the Managing Editor. The views, comments and opinions expressed within are not necessarily those of Dendrite Clinical Systems or the Editorial Board. Bariatricnews.net is a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

bottom of page